Phase I Open-label, Dose Escalation Trial of BI 1831169 Monotherapy and in Combination With an Anti-PD-1 mAb in Patients With Advanced or Metastatic Solid Tumors
Latest Information Update: 13 Jun 2025
At a glance
- Drugs BI 1831169 (Primary) ; BI 1831169 (Primary) ; Ezabenlimab (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Boehringer Ingelheim
Most Recent Events
- 15 Apr 2025 Planned primary completion date changed from 3 May 2027 to 13 Dec 2027.
- 03 Apr 2025 Planned End Date changed from 3 May 2028 to 31 Oct 2028.
- 31 May 2024 Planned number of patients changed from 117 to 190.